Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

This study is testing whether adding a drug called nimotuzumab (an antibody that targets a protein called EGFR, which many cancer cells overproduce) to standard chemoradiotherapy improves outcomes in people with esophageal squamous cell cancer. Participants will also receive nutritional support as part of the study. **You may be eligible if...** - You have been diagnosed with squamous cell carcinoma of the esophagus (confirmed by biopsy) - You have not yet received any treatment for esophageal cancer - You are in generally good health (KPS score 70 or higher) - You show signs of nutritional risk (NRS-2002 score of 2 or higher) - Your blood counts, liver function, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have already received surgery, radiation, or chemotherapy for this cancer - You have another type of cancer (with limited exceptions for previously cured skin cancer or cervical carcinoma in situ) - Your cancer has spread to distant organs (such as bones, brain, lungs, or liver) - You have an active infection, significant heart or lung problems, or inflammatory bowel disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.